Coronado Biosciences Reports Financial Results for the Third Quarter; KYTHERA to Release Third Quarter 2013 Operating Results Print E-mail
By Staff and Wire Reports   
Friday, 01 November 2013 19:55
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 1, 2013.

Coronado Biosciences, Inc. (Nasdaq:CNDO)
, a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the third quarter ended September 30, 2013.

Coronado reported net losses of $7.8 million and $27.4 million for the three and nine months ended September 30, 2013, respectively, compared to net losses of $5.9 million and $18.9 for the three and nine months ended September 30, 2012, respectively.

Research and development expenses were $5.4 million and $19.1 million for the three and nine months ended September 30, 2013, respectively, compared to $3.8 million and $12.9 million for the three and nine months ended September 30, 2012, respectively. The increases in research and development expenses relate primarily to increased clinical activities in the TSO development program.

General and administrative expenses totaled $2.1 million and $7.1 million for the three and nine months ended September 30, 2013, respectively, compared to $2.1 million and $6.0 million for the three and nine months ended September 30, 2012, respectively. The increase in general and administrative expenses for the nine months ended September 30, 2013, compared to the nine months ended September 30, 2012, related primarily to the company's infrastructure growth and increased business activity. At September 30, 2013, Coronado's cash totaled $106.3 million.



==========================



KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH)
today announced it will release its third quarter 2013 operating results and will host an investor call and webcast at 1:30 p.m. PST on Thursday, November 14, 2013.

Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number 90439630. To access the webcast, please visit the Investors section of KYTHERA's website at www.kytherabiopharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting November 14, 2013, at approximately 4:30 p.m. PST, running through 11:59 p.m. PST on November 20, 2013. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 90439630. The archived webcast will be available on KYTHERA's website for seven days beginning approximately one hour after the call has completed.



Also Friday:




Aastrom Biosciences, Inc. (Nasdaq:ASTM)
, the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that results from two separate research studies involving ixmyelocel-T, the company's lead product candidate, were published in the peer reviewed journal Stem Cell Research & Therapy.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
today announced the appointment of Jude Dinges as Senior Vice President, Chief Commercial Officer, thus reaffirming its new vision of becoming a specialty biopharmaceutical commercially operating company.

Altravax, Inc. today announced the appointment of Dr. Sean X. Du to the role of Chief Operating Officer. He joins Altravax from Simcere Pharmaceuticals Group (NYSE:SCR) where he was Executive Director, Institute of Vaccine Research. Dr. Du established Simcere's R&D capabilities for new generation vaccines and was also involved in the evaluation of vaccine-related collaborations and M&A opportunities.

Ambit Biosciences (Nasdaq: AMBI)
, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report third quarter 2013 operational results after closing of the NASDAQ Global Market on Thursday, November 7, 2013.

ARRAYit Corporation (OTCQB: ARYC)
reports that it has received a $72,297 purchase order from ChemBio, the company's high-powered distributor in Moscow, Russia. ChemBio, which is Russia's premiere distributor of life sciences products and services, represents ARRAYit, Corning, Molecular Devices, Nalgene and other leading corporations, providing Russian customers with market information, technical assistance, installation, product support and training.

Digirad Corporation (Nasdaq:DRAD)
today reported third quarter earnings of $2.5 million, or $0.14 per diluted share, with total revenues of $12.4 million. Ending cash, cash equivalents and available-for-sale securities was $25.9 million.

Dyadic International, Inc. (OTC Pink: DYAI)
, a global biotechnology company, today announced that it will report its financial results for the third quarter ended September 30, 2013 after market close on Thursday, November 14, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.

Halozyme Therapeutics, Inc. (NASDAQ: HALO)
will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013 at 8:30 a.m. ET/5:30 a.m. PT.

Ingen Technologies Inc. (OTC:IGNT)
, a holding company with revenue generating subsidiaries in Medical Device Manufacturing and Telecom Services Industries announces today that the company has received more purchase orders and has delivered 100 more Oxyview units to the world renowned UK based Topout company and leader in high altitude oxygen delivery systems for serious mountain climbing adventures worldwide. Ingen's Oxyview product recently went to the top of Mt. Everest.

Insmed Incorporated (NASDAQ: INSM)
, a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced the appointment of David W.J. McGirr to its Board of Directors.

MELA Sciences, Inc. (Nasdaq:MELA)
the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced the closing of its previously announced registered offering.

MWI Veterinary Supply, Inc. (NASDAQ: MWIV)
announced today that it has completed its previously announced acquisition of substantially all of the assets of IVESCO Holdings LLC for an enterprise value of $67.5 million, plus a closing net working capital adjustment of $11.2 million.

Neogen Corporation (NASDAQ: NEOG)
announced today that it has acquired the assets of Prima Tech Incorporated, a veterinary instrument company based in Kenansville, North Carolina.

With October behind us, Nuvilex, Inc. (OTCQB: NVLX)
investors should see a new acquisition this month. Two weeks ago Stock Market Media Group, a research and content development investor relations firm, released an audio interview with Nuvilex's COO, Dr. Gerald Crabtree, where he discussed many topics including; the company's future Phase III clinical trials, study sites, the goals of the trials, and why he feels the company's unique live-cell encapsulation-based platform technology is better than any other cell encapsulation out there.

Premier, Inc. (Nasdaq:PINC)
has introduced new radiation safety offerings in its contract portfolio to help providers better protect patients and healthcare workers.

Pharmacyclics, Inc. (Nasdaq: PCYC)
today announced that it will hold a conference call and audio webcast to discuss financial results for its third quarter ended September 30, 2013 and recent developments after the NASDAQ Market closes on Thursday, November 7, 2013 at 4:30 p.m. ET.

The Radiant Creation Group, Inc. (OTCBB: RCGP)
, developer of unique, proprietary scientific technologies and cosmetic over-the-counter products, is pleased to announce the launch of our direct to consumer sales model.

RCM Technologies, Inc. (Nasdaq:RCMT)
, a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced information technology, engineering and specialty healthcare services, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2013 Annual Meeting of Stockholders, to be held on Thursday, December 5, 2013, at 6:00 p.m., at the offices of Morgan, Lewis & Bockius LLP in Philadelphia, Pennsylvania.

Repligen Corporation (Nasdaq:RGEN)
today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met.

St. Jude Medical, Inc. (NYSE:STJ)
will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, Nov. 13, in Scottsdale, AZ.

Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM)
, a leading developer of RNA interference (RNAi) therapeutics, today announced the closing of the full over-allotment option to purchase an additional 562,500 shares at a price of $8.00 per share granted to the underwriters in connection with Tekmira's previously completed public offering of common stock, increasing the total gross proceeds to US$34.5 million.

VIVUS, Inc. (Nasdaq:VVUS)
today announced that it will report financial results for the third quarter ended September 30, 2013 after the NASDAQ Market closes on Tuesday, November 5, 2013.

Zogenix, Inc. (Nasdaq:ZGNX)
, a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that it has entered into a Development and Option Agreement ("D&O Agreement") with Altus Formulation Inc. ("Altus"), a private Montreal-based drug formulation and development company, to develop abuse deterrent formulations of Zohydro™ ER (hydrocodone bitartrate) extended-release capsules, using Altus's proprietary Intellitab™ drug delivery platform.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter